Singapore Clinical Trial: ROSETTA CRC-203: A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination with Chemotherapy Versus Bevacizumab in Combination with Chemotherapy in Participants with Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

Singapore, April 3 -- The Health Sciences Authority received information related to the study titled 'ROSETTA CRC-203: A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination with Chemothera... Read More

Singapore Clinical Trial: Leveraging AS01-induced immune cell reprogramming to modulate immune dysregulation in rheumatoid arthritis

Singapore, April 3 -- The Health Sciences Authority received information related to the study titled 'Leveraging AS01-induced immune cell reprogramming to modulate immune dysregulation in rheumatoid a... Read More

Singapore Clinical Trial: A Phase I/II open label study of DJI136, a DLL3-targeted CAR-T therapy, in adult patients with ES-SCLC

Singapore, April 3 -- The Health Sciences Authority received information related to the study titled 'A Phase I/II open label study of DJI136, a DLL3-targeted CAR-T therapy, in adult patients with ES-... Read More

Singapore Clinical Trial: Beamion PANTUMOR 1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2 mutated or overexpressed/amplified solid tumours

Singapore, April 3 -- The Health Sciences Authority received information related to the study titled 'Beamion PANTUMOR 1: A Phase II, multicentre, multicohort, open-label trial to evaluate the efficac... Read More

Singapore Clinical Trial: An open-label, multi-center, phase I/Ib study of IEV407 as a single agent and in combination with endocrine therapy in patients with advanced hormone receptor positive, HER2- negative breast cancer

Singapore, April 3 -- The Health Sciences Authority received information related to the study titled 'An open-label, multi-center, phase I/Ib study of IEV407 as a single agent and in combination with ... Read More

Singapore Clinical Trial: A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of L606 (Treprostinil Liposome Inhalation Suspension) in Participants with Pulmonary Hypertension Associated with Interstitial Lung Disease (WHO Group 3)

Singapore, April 3 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safet... Read More

Singapore Clinical Trial: DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PLOZASIRAN IN ADULTS WITH SEVERE HYPERTRIGLYCERIDEMIA AT HIGH RISK OF ACUTE PANCREATITIS (SHASTA-5 STUDY)

Singapore, April 3 -- The Health Sciences Authority received information related to the study titled 'DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PLOZASIRAN ... Read More

Singapore Clinical Trial: A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Investigator’s Choice (IC) in Patients with Endometrial Cancer After Platinum-Based Chemotherapy and PD(L)-1 Therapy

Singapore, April 3 -- The Health Sciences Authority received information related to the study titled 'A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Invest... Read More

Singapore Clinical Trial: A Phase III, Randomized, Open-Label, Multicenter, Global Study of Puxitatug Samrotecan (AZD8205) Monotherapy versus Physician’s Choice of Chemotherapy in Participants with B7-H4-Selected Advanced/Metastatic Endometrial Cancer Who Progressed On or After Platinum-Based Chemotherapy and Anti-PD-1/Anti-PD-L1 Therapy (BLUESTAR-Endometrial01)

Singapore, April 3 -- The Health Sciences Authority received information related to the study titled 'A Phase III, Randomized, Open-Label, Multicenter, Global Study of Puxitatug Samrotecan (AZD8205) M... Read More

Singapore Clinical Trial: A Multicenter, Randomized, Double-blind, Phase 2/3 Study of Ficerafusp Alfa (BCA101) or Placebo in Combination with Pembrolizumab for First-Line Treatment of PD-L1-positive, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Singapore, April 3 -- The Health Sciences Authority received information related to the study titled 'A Multicenter, Randomized, Double-blind, Phase 2/3 Study of Ficerafusp Alfa (BCA101) or Placebo in... Read More

• ««
• «
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• »
• »»